tobramycin treatment infection due pseudomonas aeruginosa patient cystic fibrosis effectiveness safety tobramycin infection due pseudomonas aeruginosa patient cystic fibrosis studied 15 patient moderatetosevere exacerbation chronic pulmonary infection seventeen course treatment given tobramycin 575 mgkg per day administered intravenously three divided dos per day seven 21 day specimen sputum yielded moderatetoheavy growth p aeruginosa isolates inhibited 4 mug tobramycinml seven case isolates inhibited 4 mug gentamicinml mean level tobramycin blood 44 mugml 051 hr 08 mugml 758 hr administration patient received antistaphylococcal agent therapy patient except two received 750 mg carbenicillinkg per day intravenously six divided dos 1 g carbenicillin mask inhalation three time day clinical radiological improvement noted patient white blood cell count elevated seven patient returned normal level blood gas improved p aeruginosa eliminated sputum five case adverse side effect noted